Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

PVRIG Antibody

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Drug Derivative (1) Transmembrane Glycoprotein (1)
By Research Areas:	Cancer (1) Inflammation/Immunology (3)

Inhibitors & Agonists

Inhibitory Antibodies

Antibodies

Targets Recommended: ADC Antibody Antibody-Drug Conjugates (ADCs) Antibody-Oligonucleotide Conjugates (AOCs) ADC Linker PROTAC-Linker Conjugates for PAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P990496

Anti-PVRIG Antibody (COM701) COM701	Transmembrane Glycoprotein	Inflammation/Immunology
Anti-PVRIG Antibody (COM701) is a CHO-expressed human antibody that targets *PVRIG. The predicted molecular weight (MW) of Anti-PVRIG* Antibody (COM701) is 145.48 kDa. The isotype control for Anti-PVRIG Antibody (COM701) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).

HY-P992381

IBI352g4a	Drug Derivative	Cancer
IBI352g4a is a humanized IgG1 monoclonal antibody targeting *PVRIG* (K_d = 0.53 nM) and acts as a *PVRIG/PVRL2* inhibitor. The anti-tumor effect of IBI352g4a depends on the binding of its Fc region to FcγR. IBI352g4a binds to the extracellular domains of human and cynomolgus monkey PVRIG, and blocks the PVRIG-PVRL2 interaction. IBI352g4a induces NK cell activation, promotes their degranulation and tumor killing. IBI352g4a can be used in the research of gastric cancer .

Cat. No.	Product Name	Target	Research Area	Image

HY-P990496

Anti-PVRIG Antibody (COM701) COM701	Transmembrane Glycoprotein	Inflammation/Immunology
Anti-PVRIG Antibody (COM701) is a CHO-expressed human antibody that targets *PVRIG. The predicted molecular weight (MW) of Anti-PVRIG* Antibody (COM701) is 145.48 kDa. The isotype control for Anti-PVRIG Antibody (COM701) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).

HY-P990593

GSK-4381562	Inhibitory Antibodies	Inflammation/Immunology
GSK-4381562 is a CHO-expressed human antibody that targets *PVRIG*. GSK-4381562 carries a huIgG1 heavy chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for GSK-4381562 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991020

Remzistotug	Inhibitory Antibodies	Inflammation/Immunology
HY-P991020 is an *PVRIG*-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P992381

IBI352g4a	Drug Derivative	Cancer
IBI352g4a is a humanized IgG1 monoclonal antibody targeting *PVRIG* (K_d = 0.53 nM) and acts as a *PVRIG/PVRL2* inhibitor. The anti-tumor effect of IBI352g4a depends on the binding of its Fc region to FcγR. IBI352g4a binds to the extracellular domains of human and cynomolgus monkey PVRIG, and blocks the PVRIG-PVRL2 interaction. IBI352g4a induces NK cell activation, promotes their degranulation and tumor killing. IBI352g4a can be used in the research of gastric cancer .

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P84955

	CD112R Antibody (YA4647) Poliovirus receptor-related immunoglobulin domain containing protein; PVRIG; C7orf15; CD112 receptor
	CD112R Antibody (YA4647) is a non-conjugated antibody, targeting to CD112R.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.